Jun 07, 2023 / 03:00PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
Thank you very much. I want to get started on the next session. I'm Michael Yee, Managing Director and Senior Biotechnology Analyst at Jefferies. I'm very happy to have with us here at Gilead Sciences, Johanna Mercier, the Chief Commercial Officer. And I thought, that would be quite perfect timing because we're coming away from ASCO. We were just talking about flying from Chicago over here to New York.
Questions and Answers:
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity AnalystAnd, a lot of developments going on in oncology for Gilead as well as, obviously, I want to spend half of this talking about the developments in HIV and all the long-acting developments, which I think is getting a lot more news because some of your competitors are talking about long-acting as well, and I think that's underappreciated.
So maybe, just in the first half of our discussion, we have come away from ASCO, and Gilead is obviously knee-deep in breast cancer with Trodelvy, and
Trustpilot
